Ir directamente a la navegación principal
Ir directamente a la búsqueda
Ir directamente al contenido principal
Scholars @ UT Health San Antonio Inicio
Ayuda y preguntas frecuentes
!!Link opens in a new tab
English
Español
Buscar contenido en Scholars @ UT Health San Antonio
Inicio
Perfiles
Unidades de investigación
Producción científica
Conjuntos de datos
Cardioprotective Effects of Pioglitazone in Type 2 Diabetes
Devjit Tripathy
,
Carolina Solis-Herrera
, Robert E.J. Ryder
Division of Diabetes
Division of Endocrinology
Producción científica
:
Article
›
revisión exhaustiva
4
!!Link opens in a new tab
Citas (Scopus)
Información general
Huella
Huella
Profundice en los temas de investigación de 'Cardioprotective Effects of Pioglitazone in Type 2 Diabetes'. En conjunto forman una huella única.
Clasificar por
Ponderación
Alfabéticamente
Medicine and Dentistry
Maturity Onset Diabetes of the Young
100%
Pioglitazone
100%
Cardiovascular System
66%
Antidiabetic Agent
66%
Thiazolidinedione
66%
Drug
66%
Chemotherapeutic Agent
66%
Low Drug Dose
33%
Hyperglycemia
33%
Glycemic Control
33%
Cardiovascular Disease
33%
Cardiovascular Risk
33%
Adverse Event
33%
Insulin Resistance
33%
Glucagon-Like Peptide-1 Agonist
33%
Cotransporter
33%
Glitazone Derivative
33%
Therapeutic Procedure
33%
Nursing and Health Professions
Non Insulin Dependent Diabetes Mellitus
100%
Pioglitazone
100%
Drug
66%
Antidiabetic Agent
66%
Cardiovascular Risk
33%
Adverse Event
33%
Drug Therapy
33%
Cardiovascular Disease
33%
Hyperglycemia
33%
Insulin Resistance
33%
Low Drug Dose
33%
Glucagon Like Peptide 1 Receptor Agonist
33%
Thiazolidinedione
33%
Cotransporter
33%
Glitazone Derivative
33%
Pharmacology, Toxicology and Pharmaceutical Science
Non Insulin Dependent Diabetes Mellitus
100%
Pioglitazone
100%
Drug
66%
Antidiabetic Agent
66%
Adverse Event
33%
Insulin Resistance
33%
Hyperglycemia
33%
Cardiovascular Risk
33%
Glucagon Like Peptide 1 Receptor Agonist
33%
Cotransporter
33%
Glitazone Derivative
33%
Neuroscience
Diabetes
100%
Pioglitazone
100%
Insulin
33%
Cotransporter
33%
Hyperglycemia
33%
Thiazolidinedione
33%
Adverse Effect
33%
Glucagon-Like Peptide-1 Receptor Agonist
33%